Niraparib: tested on its own
67 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian CancerNot yet recruitingNCT06887933Phase 4Report a problem
- Study Evaluating Safety, Tolerability, and Metabolism of NiraparibRecruitingNCT06412120Phase 4Report a problem
- Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination DeficiencyNot yet recruitingNCT06237205Phase 2Report a problem
- Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic ProgressionRecruitingNCT06180356Phase 2Report a problem
- Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabRecruitingNCT06141265Phase 2Report a problem
- SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi TherapyRecruitingNCT05990192Phase 2Report a problem
- Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian CancerRecruitingNCT05961124Phase 2Report a problem
- Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCRecruitingNCT05718323Phase 2Report a problem
- A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCErNot yet recruitingNCT05519670Phase 1/2Report a problem
- Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNot yet recruitingNCT05461690Phase 2Report a problem
- PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations CarriersNot yet recruitingNCT05232006Phase 2Report a problem
- PARP Inhibitor Oral Maintenance in Low-Risk Ovarian CancerNot yet recruitingNCT05187208Phase 4Report a problem
- Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous CarcinomaRecruitingNCT04716686Phase 2Report a problem
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyRecruitingNCT04641247Phase 2Report a problem
- PARP Inhibition for Gliomas (PI-4G or π4g)TerminatedNCT05297864Phase 2Results postedReport a problem
- Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsTerminatedNCT05169437Phase 2Results postedReport a problem
- Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular DiseaseActive, not recruitingNCT04915755Phase 3Results postedReport a problem
- Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response DefectsTerminatedNCT04030559Phase 2Results postedReport a problem
- A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric AdenocarcinomaTerminatedNCT03840967Phase 2Results postedReport a problem
- Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian CancerCompletedNCT03759600Phase 2Results postedReport a problem
- Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian CancerCompletedNCT03759587Phase 2Results postedReport a problem
- Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the CervixTerminatedNCT03644342Phase 1/2Results postedReport a problem
- A Study of Niraparib as Single Agent in Participants With Advanced Solid TumorsCompletedNCT03497429Phase 1Results postedReport a problem
- Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment PatientsCompletedNCT03359850Phase 1Results postedReport a problem
- Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast CancerCompletedNCT03329937Phase 1Results postedReport a problem
- Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib CapsuleCompletedNCT03329001Phase 1Results postedReport a problem
- A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)CompletedNCT03207347Phase 2Results postedReport a problem
- An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair AnomaliesCompletedNCT02854436Phase 2Results postedReport a problem
- A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT02655016Phase 3Results postedReport a problem
- A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensCompletedNCT02354586Phase 2Results postedReport a problem
- A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsTerminatedNCT01905592Phase 3Results postedReport a problem
- A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerCompletedNCT01847274Phase 3Results postedReport a problem
- A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated GlioblastomaActive, not recruitingNCT06388733Phase 3Report a problem
- Reirradiation and Niraparib in Patients With Recurrent GlioblastomaWithdrawnNCT05666349Phase 1Report a problem
- A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNAActive, not recruitingNCT05515575Phase 2Report a problem
- Niraparib Efficacy in Patient With Unresectable MesotheliomaCompletedNCT05455424Phase 2Report a problem
- Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic CancerTerminatedNCT05442749Phase 2Report a problem
- Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction TherapyWithdrawnNCT05412706Phase 2Report a problem
- Niraparib in High-grade Endometrial Cancer TrialWithdrawnNCT05289648Early Phase 1Report a problem
- Niraparib for the Treatment of LeiomyosarcomaWithdrawnNCT05174455Phase 2Report a problem
- Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent GliomaActive, not recruitingNCT05076513Early Phase 1Report a problem
- Niraparib in Tumors Metastatic to the CNSActive, not recruitingNCT04992013Phase 2Report a problem
- NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.TerminatedNCT04861181Phase 4Report a problem
- Niraparib Combined With Radiotherapy in rGBMStatus unknownNCT04715620Phase 2Report a problem
- Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian CancerActive, not recruitingNCT04507841Phase 2Report a problem
- A Study of Niraparib in Patients With Relapsed Ovarian CancerCompletedNCT04392102Phase 2Report a problem
- Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant SettingCompletedNCT04284852Phase 2Report a problem
- Niraparib/TTFields in GBMActive, not recruitingNCT04221503Phase 2Report a problem
- Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian CancerStatus unknownNCT04217798Phase 2Report a problem
- A Study of Various Treatments in Serous or p53 Abnormal Endometrial CancerTerminatedNCT04159155Phase 2/3Report a problem
- Trial of Maintenance With Niraparib- Uterine Serous CarcinomaCompletedNCT04080284Phase 2Report a problem
- A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsActive, not recruitingNCT03945721Phase 1Report a problem
- Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based ChemotherapyCompletedNCT03945084Phase 2Report a problem
- Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) MutationStatus unknownNCT03925350Phase 2Report a problem
- Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)TerminatedNCT03891576Phase 2Report a problem
- NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.CompletedNCT03752216Phase 4Report a problem
- A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian CancerStatus unknownNCT03709316Phase 3Report a problem
- Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer PatientStatus unknownNCT03705156Phase 3Report a problem
- Niraparib in Patients With Pancreatic CancerCompletedNCT03601923Phase 2Report a problem
- The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian CancerCompletedNCT03551171Phase 1Report a problem
- A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT03516084Phase 3Report a problem
- Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)CompletedNCT03076203Phase 1Report a problem
- A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer PatientsTerminatedNCT02826512Phase 2Report a problem
- Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With CancerCompletedNCT02476552Phase 1Report a problem
- A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)WithdrawnNCT01244009Phase 2Report a problem
- A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)TerminatedNCT01226901Phase 1Report a problem
- A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)CompletedNCT00749502Phase 1Report a problem